Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab ADC

CAR-T Digest - August 2020

06 Feb 2024: Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab ADC

Nascent Biotech, pioneering the development of mAbs collaborates with Manhattan BioSolutions to explore antibody-drug conjugates using Nascent’s lead clinical candidate, pritumumab (PTB)
PTB, a human antibody, targets vimentin, a protein linked to cancer growth, particularly in brain and pancreatic cancers, as well as other hard tumors
Preclinical experiments indicate PTB’s ability to cross the blood-brain barrier and transport drugs into brain tissues, with Nascent holding a patent for this delivery mechanism.
PTB shows promise in safety and efficacy based on Phase I trial in glioblastoma patients. Nascent cleared by FDA to start Phase II trials for brain cancer treatment with PTB.
The collaboration aims to unlock PTB’s potential in targeted cancer therapy, with both Nascent and Manhattan Bio expressing enthusiasm for the project’s potential impact